A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy

References

• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475–83
   PubMed Web of Science ®Google Scholar
• Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27:318–26
   PubMed Web of Science ®Google Scholar
• Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 13:160–8
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194–205
   PubMed Web of Science ®Google Scholar
• Goke B, Gallwitz B, Eriksson JG, et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013;67:307–16
   PubMed Web of Science ®Google Scholar
• Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007;23:919–31
   PubMed Web of Science ®Google Scholar
• Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 2014;57:3205–12
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461–70
   Google Scholar
• Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Stats 2000;62:134–48
   Google Scholar
• Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015;109:378–88
   PubMed Web of Science ®Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213–26
   PubMed Web of Science ®Google Scholar
• Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: John Wiley & Sons; 1987.
   Google Scholar
• Goldenberg R, Gantz I, Andryuk PJ, et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2017;19:394–400
   PubMed Web of Science ®Google Scholar
• Gantz I, Okamoto T, Ito Y, et al. Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial. Diabetologia 2014;57(S1):S55
   Web of Science ®Google Scholar
• Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2010;6:225–35
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996;19:849–56
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocr Pract 2017;23:207-38
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Rosenstock J, Patel S, et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial. Diabetes Obes Metab 2015;17:276–84
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals I. Bydureon Medical Review. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000MedR.pdf. Accessed April 5, 2016
   Google Scholar
• Boehringer Ingleheim Pharmaceuticals I. Linagliptin Medical Review. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000MedR.pdf. Accessed April 5, 2016
   Google Scholar
• Sheu WH, Gantz I, Chen M, et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care 2015;38:2106–14
   PubMed Web of Science ®Google Scholar